PN-1 Inhibitor Partial Dosage for Metastasis Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies fail to effectively inhibit metastasis, particularly in solid tumors, as complete inhibition of protease nexin-1 (PN-1) does not prevent metastasis, while partial inhibition is not adequately explored for therapeutic benefit.
Innovation Solution
A method involving the administration of a PN-1 inhibitor at a therapeutic dosage that partially inhibits PN-1 expression and activity, specifically targeting cancer cells by reducing matrix metalloproteinase-9 (MMP-9) levels and metastatic properties without affecting PAI1 levels, suitable for various cancer types including breast, prostate, and oral squamous carcinoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If complete inhibition of PN-1 is achieved, then metastatic properties should be reduced, but complete inhibition does not effectively prevent metastasis
Solution Approach 1:
The patent applies partial inhibition of PN-1 rather than complete inhibition. The inhibitor is administered at a dosage that partially reduces PN-1 expression and activity, which effectively decreases MMP-9 levels and metastatic properties while avoiding the ineffectiveness of complete inhibition. This principle resolves the contradiction by finding an optimal partial inhibition level that achieves therapeutic benefit without the drawbacks of complete inhibition.
Solution Approach 2:
The patent changes the parameter of PN-1 inhibition level from complete to partial. By adjusting the dosage of the PN-1 inhibitor, the treatment achieves a specific inhibition level (partial rather than complete) that optimizes metastasis prevention. This parameter change resolves the technical contradiction by transforming the inhibition approach from all-or-nothing to a controlled partial inhibition that is therapeutically effective.
2Reliability
If PN-1 inhibitor is administered to reduce metastasis, then MMP-9 expression decreases, but dosage optimization is required to avoid complete inhibition
Solution Approach 1:
The patent optimizes the dosage parameter of the PN-1 inhibitor to achieve partial inhibition. By carefully controlling the dosage, the treatment reduces MMP-9 expression and metastatic properties while maintaining PN-1 at levels that prevent metastasis. This dosage optimization resolves the contradiction between achieving effective inhibition and avoiding complete inhibition.
Solution Approach 2:
The patent employs feedback control in dosage optimization. The inhibitor dosage is adjusted based on the observed effects on MMP-9 levels and metastatic properties, ensuring that partial inhibition is achieved without complete suppression of PN-1. This feedback mechanism resolves the contradiction by dynamically optimizing the dosage to maintain therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Partial inhibition of PN-1 effectively decreases metastatic properties and MMP-9 expression in cancer cells, offering a targeted therapeutic approach for treating and preventing metastasis in solid tumors without complete inhibition of PN-1.
Implementation Method 1
PN-1 can inhibit activity of a broad range of enzymes, such as tissue plasminogen activator (tPA), Urokinase-type plasminogen activator (uPA), thrombin, factor XIa, prostasin
Data Source
AI summary
The present invention relates to a method of inhibiting metastasis comprising the administration of an inhibitor of protease nexin-1 (PN-1), characterized in that said inhibitor is administered at a therapeutical dosage that does not completely inhibit the expression and/or activity of PN-1.